POEMS Syndrome — Structured Data

AI-optimized single page. All data for POEMS Syndrome in dense, structured format. Last updated: 2026-03-30.

View interactive disease hub · View all sources

Key Statistics

Total reported cases: Unknown
Mean onset age: 52 years
Onset range: 21–84 years
Sex ratio (M:F): 1.5:1
Diagnostic delay: ~1.5 years
Discovered: 1956 (R.S. Crow (first description); P.A. Bardwick (coined POEMS acronym, 1980))
Prevalence: <1/1,000,000
Classification: hematologic, paraneoplastic
Pathophysiology: partially understood
Treatment status: effective options available
Genetic basis: under investigation
Aliases: POEMS, Crow-Fukase Syndrome, Takatsuki Syndrome, Osteosclerotic Myeloma, PEP Syndrome, Polyneuropathy Organomegaly Endocrinopathy Monoclonal protein Skin changes

Symptoms (13)

Symptom	Frequency	Severity	Category	Description
Polyneuropathy	100%	cardinal	neurologic	Progressive ascending symmetric sensorimotor demyelinating polyneuropathy. Starts with distal numbness and tingling in feet, progressing to motor weakness. Uniform demyelination (intermediate segments) with severe axonal loss in lower limbs. Distinguished from CIDP by less conduction block, less temporal dispersion, and absent sural sparing.
Monoclonal plasma cell disorder (lambda-restricted)	100%	cardinal	laboratory	Clonal plasma cell proliferative disorder with >95% lambda light chain restriction. Characteristically uses IGLV1-44 or IGLV1-40 germline gene segments. Bone marrow plasma cell percentage is typically low (<5% in most cases), unlike multiple myeloma.
Elevated VEGF	96%	major	laboratory	Serum VEGF levels typically 5-10 fold above normal (median ~4000 pg/mL). Serum VEGF >1000 pg/mL with demyelinating neuropathy and lambda monoclonal protein has 100% sensitivity and 93% specificity for POEMS. Plasma VEGF avoids platelet-derived confounding. Levels correlate with disease activity and decline with treatment.
Sclerotic bone lesions	95%	major	skeletal	Osteosclerotic (not lytic) bone lesions are characteristic. Present in ~95% of patients. Can be solitary or multiple. Distinguished from myeloma by sclerotic rather than lytic pattern. CT is more sensitive than plain radiographs. PET-CT may show FDG avidity.
Skin changes	90%	major	dermatologic	Present in ~90% of patients. Hyperpigmentation and hemangioma most common (47%). Other features include hypertrichosis (38%), acrocyanosis (34%), Raynaud phenomenon (20%), sclerodermoid changes (26%), white nails (30%), and clubbing (6%). Glomeruloid hemangioma (~3%) is pathognomonic for POEMS.
Endocrinopathy	84%	major	endocrine	84% have recognized endocrinopathy at diagnosis; 92% develop one during follow-up. Hypogonadism most common (79% of men). Hypothyroidism (20-36%), hyperprolactinemia (56-63%), abnormal glucose metabolism (48%), and adrenal insufficiency (14%) also prevalent. Mechanisms poorly understood. Baseline hypothyroidism predicts worse PFS and OS.
Extravascular volume overload	80%	major	systemic	Peripheral edema, ascites, pleural effusion, and pericardial effusion. Present in ~80% of patients. Driven by VEGF-mediated increased vascular permeability. Pleural effusion is an independent risk factor for poor OS. Resolves with successful treatment of the plasma cell clone.
Organomegaly	50%	major	systemic	Hepatomegaly, splenomegaly, and/or lymphadenopathy present in approximately 50% of patients. Lymphadenopathy may show Castleman disease-like histology. Spleen and liver enlargement likely VEGF-driven.
Thrombocytosis / Polycythemia	54%	minor	laboratory	Thrombocytosis in ~54% of patients (vs 1.5% in CIDP). Polycythemia in ~15%. Distinguishes POEMS from myeloma (which causes thrombocytopenia). VEGF stimulates megakaryocyte proliferation. Platelet count normalizes with successful treatment.
Papilledema	52%	major	ophthalmic	Bilateral papilledema present in 29-64% of patients. Usually asymptomatic but may cause headaches, brief visual obscurations, scotomata, and visual field constriction. Not associated with raised intracranial pressure. Cause unknown but likely VEGF-mediated. Associated with unfavorable prognosis.
Pulmonary hypertension	40%	major	cardiopulmonary	Present in 33-48% of patients. Associated with dyspnea (50% of PH patients vs 19% without). Patients with PH have worse median survival (54 months vs not reached). Responds to treatment of the underlying plasma cell clone. May be steroid-responsive.
Castleman disease (co-occurring)	20%	major	hematologic	Present in 11-30% of POEMS patients. Typically multicentric Castleman disease with plasma cell variant histology. Shares IL-6 and VEGF elevation. The Castleman disease variant of POEMS has no clonal plasma cell disorder and typically less peripheral neuropathy. Histologically shows atrophied germinal centers with concentrically arranged mantle zones.
Hyperpigmentation	47%	minor	dermatologic	Most common cutaneous manifestation along with hemangioma (47%). Usually diffuse but can be localized, affecting extensor surfaces, neck, axilla, and back. Represents increased melanin production without increased melanocyte number. Similar mechanism to Addison disease pigmentation.

Molecular Pathway (7 molecules)

Molecule	Role	Expression change	Evidence level	Targeted by	Explanation
VEGF (Vascular Endothelial Growth Factor)	Central pathogenic driver — mediates vascular permeability, edema, organomegaly, neuropathy	Markedly elevated (5-10x normal)	established	Bevacizumab (disappointing results; insufficient alone)	VEGF is the central cytokine driving POEMS manifestations. Serum levels are typically 5-10 fold above normal and correlate with disease activity. VEGF drives increased vascular permeability causing edema, ascites, pleural effusion, papilledema, and contributes to peripheral nerve demyelination via increased endoneural pressure. Paradoxically, single-cell analysis shows VEGF is NOT produced by the clonal plasma cells themselves — IL-6 from clones induces VEGF production in surrounding cells.
IL-6 (Interleukin-6)	Upstream inducer of VEGF — overexpressed by clonal plasma cells	Elevated	strong	Siltuximab (anti-IL-6, used in Castleman disease)	IL-6 is a pro-inflammatory cytokine elevated in POEMS syndrome. Single-cell RNA-Seq (Isshiki et al. 2022) showed that clonal plasma cells in POEMS overexpress IL-6 but NOT VEGF, positioning IL-6 as the upstream driver. IL-6 stimulates VEGF production by surrounding stromal and immune cells. Also drives systemic inflammation, osteosclerosis, and Castleman disease-like lymph node changes. Identified as a highly prognostic biomarker.
IL-12 (Interleukin-12)	Novel biomarker — consistently elevated and correlates with disease activity	Markedly elevated	moderate	—	IL-12 was found to be markedly increased in all 23 POEMS patients studied (Kanai et al. 2012). Both IL-12 and VEGF decreased significantly with treatment, correlating with clinical improvement. Unlike other cytokines (IL-6, TNF-alpha) which are elevated in only some patients, IL-12 was consistently elevated in all patients, suggesting it may be a more reliable biomarker alongside VEGF.
IL-1beta (Interleukin-1 beta)	Pro-inflammatory cytokine elevated in POEMS	Elevated	moderate	—	IL-1beta is part of the broad pro-inflammatory cytokine network elevated in POEMS. Gherardi et al. (1996) showed IL-1beta, TNF-alpha, and IL-6 are higher in POEMS than in multiple myeloma. The antagonistic response (IL-1ra elevation) is insufficient to counteract the pro-inflammatory drive. May contribute to neuropathy and systemic inflammation.
TNF-alpha (Tumor Necrosis Factor alpha)	Pro-inflammatory cytokine elevated in POEMS	Elevated	moderate	Lenalidomide, Thalidomide (indirect via IMiD mechanism)	TNF-alpha is part of the pro-inflammatory cytokine milieu in POEMS. Elevated compared to multiple myeloma patients. Contributes to systemic inflammation, vascular dysfunction, and possibly neuropathy. Targeted indirectly by immunomodulatory drugs (lenalidomide, thalidomide) which inhibit TNF-alpha secretion.
Immunoglobulin Lambda Light Chain (IGLV1-44/IGLV1-40)	Monoclonal protein produced by clonal plasma cells — near-universal lambda restriction	Monoclonal overproduction	established	—	Over 95% of POEMS cases have lambda light chain restriction. The variable regions are highly restricted to IGLV1-4401 (~80%) and IGLV1-4001 (~20%), with conserved stereotypic amino acid changes in CDR1 and FR2 regions. This extreme restriction, unique among plasma cell disorders, suggests antigen-driven selection. The monoclonal protein itself may contribute to neuropathy through direct nerve damage or immune-mediated mechanisms.
TGF-beta1 (Transforming Growth Factor beta 1)	Anti-inflammatory cytokine — paradoxically decreased in POEMS	Decreased	moderate	—	TGF-beta1 is an anti-inflammatory cytokine that normally counterbalances pro-inflammatory signals. In POEMS, TGF-beta1 is decreased while pro-inflammatory cytokines (IL-1beta, IL-6, TNF-alpha) are elevated. This imbalance — weak or decreased antagonistic reaction insufficient to counteract noxious cytokine effects — may explain the multi-organ inflammatory damage.

Genetic Findings (5)

Gene	Variant	Type	Frequency in disease	Significance	Also found in
IGLV1-44	Stereotypic lambda light chain gene usage (IGLV1-44*01)	somatic	~80% of POEMS patients	Near-universal lambda restriction with IGLV1-44 germline usage. Conserved amino acid changes in CDR1 (T to P/A) suggest antigen-driven clonal selection unique to POEMS syndrome.	—
IGLV1-40	Stereotypic lambda light chain gene usage (IGLV1-40*01)	somatic	~20% of POEMS patients	Second most common IGLV germline in POEMS. Conserved amino acid changes at positions D to G and H to N in CDR1 and FR2. Together with IGLV1-44, accounts for nearly all POEMS cases.	—
KLHL6	Recurrently mutated (somatic)	somatic	Recurrent in WES cohorts	One of 7 recurrently mutated genes identified by Nagao et al. (2019) in POEMS plasma cells. KLHL6 is involved in B-cell receptor signaling and germinal center B-cell formation. Mutations may contribute to aberrant B-cell differentiation.	Diffuse large B-cell lymphoma (~5%)
CUX1	Recurrently mutated (somatic)	somatic	19% (Chen et al. 2021)	Most frequently mutated gene in the Chen et al. (2021) targeted sequencing cohort. CUX1 is a transcription factor involved in cell cycle regulation. Loss-of-function mutations may contribute to clonal expansion.	Myeloid neoplasms (Variable)
MYD88	Somatic mutations (including L265P)	somatic	Rare (identified in Chen et al. 2021 WES)	MYD88 mutations detected in some POEMS patients, though at lower frequency than in Waldenstrom macroglobulinemia (>90%). Drives NF-kB activation. Overlap with Waldenstrom and Schnitzler syndrome pathogenesis.	Waldenstrom macroglobulinemia (>90%); Schnitzler syndrome (~30%)

Treatment Evidence Matrix (7 treatments)

Drug	Mechanism	Route	Response rate	Onset	IgM effect	Line	Explanation
Radiation Therapy	Targeted irradiation of solitary or limited (1-3) plasmacytomas	External beam RT, median 45 Gy (range 35-54 Gy)	97% OS at 4 years	3-36 months for full clinical improvement	N/A (targets the plasma cell clone directly)	1st	For patients with 1-3 bone lesions and negative bone marrow, radiation is first-line and potentially curative. In the Mayo Clinic series (38 patients), 4-year OS was 97% and event-free survival was 52%. Symptoms improve over 3-36 months. More than half of treatment failures occurred within 12 months. Patients failing radiation can proceed to systemic therapy.
Autologous Stem Cell Transplant (ASCT)	High-dose chemotherapy followed by stem cell rescue — eradicates plasma cell clone	IV (conditioning + stem cell infusion)	5-year PFS 75%; neurologic improvement near-universal	Months (hematologic), 6-12 months (neurologic)	N/A	1st	For transplant-eligible patients with disseminated disease, ASCT achieves excellent outcomes. The Mayo Clinic series (59 patients) showed 98% PFS at 1 year, 75% at 5 years. VEGF response pre-ASCT predicts better outcomes (5-year clinical PFS 90.9% vs 47.4%). In the comparative study (Zhao et al. 2019), ASCT had the highest hematologic CR rate (49.7%) among first-line options. Pulmonary morbidity improves post-ASCT.
Lenalidomide + Dexamethasone	Immunomodulatory drug (IMiD) — inhibits IL-6, TNF-alpha, and VEGF; stimulates T-cell immunity; direct anti-plasma-cell effect via cereblon-mediated degradation of Ikaros/Aiolos	Oral lenalidomide 10-25 mg days 1-21 + dexamethasone 40 mg weekly, 28-day cycles	Hematologic CR 46%, neurologic response 95%, VEGF response 83%	Median VEGF response: 2 months; neurologic improvement: 3-6 months	N/A	1st	In the Phase II trial (He et al. 2018, 41 newly diagnosed patients), low-dose lenalidomide (10 mg) + dexamethasone achieved hematologic CR in 46%, neurologic response in 95%, and VEGF response in 83%. 3-year OS 90%, PFS 75%. Well tolerated with no treatment-related deaths or grade 3+ lenalidomide toxicity. Also effective in relapsed/refractory setting (77% hematologic response). High cereblon expression predicts better response.
Melphalan + Dexamethasone (MDex)	Alkylating agent — directly cytotoxic to plasma cells; dexamethasone adds anti-inflammatory and anti-neoplastic effect	Oral melphalan + dexamethasone in 4-6 week cycles	Hematologic response 81% (CR 39%), neurologic response 100%	Initial neurologic response at 3 months; maximal at 12 months	N/A	1st	Li et al. (2011) prospective study of 31 newly diagnosed patients showed hematologic response of 80.6%, neurologic response of 100%, and resolution of pulmonary hypertension in 93.3%. Well tolerated with low toxicity. Particularly effective for organomegaly (64.3% response) and extravascular volume overload (71.4% response). Avoids stem cell damage, but not preferred before ASCT as melphalan may impair stem cell collection.
Bortezomib + Dexamethasone (BDex)	Proteasome inhibitor — disrupts NF-kB signaling, induces plasma cell apoptosis	SC bortezomib + oral/IV dexamethasone, typically 3-4 week cycles	Neurologic response 88%, hematologic CR 46%, VEGF response 71%	Weeks to months	N/A	1st	He et al. (2021) studied 69 patients treated with frontline BDex. Neurologic response rate was 88.1%, hematologic CR 46.4%, and VEGF response 71.2%. Well tolerated despite historical concerns about neuropathy — only 2 patients developed grade 1 bortezomib-induced neuropathy, which was reversible. No treatment-related deaths. Does not impair stem cell collection, making it suitable before planned ASCT.
Thalidomide + Dexamethasone	Immunomodulatory drug (IMiD) — anti-angiogenic, anti-proliferative, anti-cytokine properties	Oral thalidomide 200 mg daily + dexamethasone, 4-week cycles	VEGF reduction rate 0.39 (J-POST RCT)	Weeks to months	N/A	1st	The only drug proven in a randomized controlled trial (J-POST, Misawa et al. 2016). The J-POST trial randomized POEMS patients ineligible for ASCT to thalidomide+dex vs placebo+dex. Significant VEGF reduction (p=0.04) with thalidomide. First-line treatment in Japan. Sinus bradycardia is the most common side effect (54%). Lenalidomide is effective in thalidomide-refractory cases.
Bevacizumab (anti-VEGF)	Monoclonal antibody targeting VEGF — blocks VEGF-mediated vascular permeability	IV infusion	Ambiguous — VEGF drops but clinical benefit inconsistent; deaths reported	VEGF decreases rapidly; clinical response unreliable	N/A	Not recommended	Despite lowering VEGF levels, bevacizumab has produced disappointing clinical results. In a series of 6 patients (Kanai et al. 2013), 4 had no response and 2 died. In the broader literature, 6 of 17 patients died without showing response. Failure likely because multiple cytokines (IL-6, IL-12, TNF-alpha) drive disease beyond VEGF alone. Sudden VEGF removal may also cause collapse of fragile new vessels, worsening capillary leak. Not recommended as monotherapy; possible bridge to definitive treatment.

Diagnostic Criteria

Dispenzieri (Mayo Clinic) Criteria (2019)

Sensitivity: ~95% · Specificity: ~95%

Major criteria (all required)

Mandatory: Polyneuropathy (typically demyelinating)
Mandatory: Monoclonal plasma cell proliferative disorder (almost always lambda light chain restricted)
Major: Sclerotic bone lesions
Major: Castleman disease
Major: Elevated VEGF

Minor criteria (1+ required)

Organomegaly (splenomegaly, hepatomegaly, or lymphadenopathy)
Extravascular volume overload (edema, pleural effusion, or ascites)
Endocrinopathy (adrenal, thyroid, pituitary, gonadal, parathyroid, pancreatic — diabetes and thyroid abnormalities alone not sufficient)
Skin changes (hyperpigmentation, hypertrichosis, glomeruloid hemangiomata, plethora, acrocyanosis, flushing, white nails)
Papilledema
Thrombocytosis/polycythemia

Both mandatory criteria required, plus at least 1 major criterion and at least 1 minor criterion. Not all features of the POEMS acronym need be present. Other features not in criteria but associated: clubbing, weight loss, hyperhidrosis, pulmonary hypertension, restrictive lung disease, thrombotic diathesis, diarrhea, low vitamin B12.

Differential Diagnoses (7)

Condition	Key distinction	Shared features
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	No monoclonal protein, no VEGF elevation. CIDP shows multifocal demyelination with conduction block and temporal dispersion, while POEMS shows uniform demyelination in intermediate nerve segments with less conduction block. CIDP responds to IVIG/plasmapheresis; POEMS does not.	Demyelinating polyneuropathy, Progressive weakness, Elevated CSF protein, Nerve conduction slowing
Multiple Myeloma	Bone lesions are lytic (not sclerotic). Cytopenias (especially thrombocytopenia) rather than thrombocytosis. Higher plasma cell burden. Peripheral neuropathy uncommon (<5%). VEGF not characteristically elevated. Driver mutations (NRAS, KRAS, BRAF, TP53) present in myeloma but absent in POEMS.	Monoclonal plasma cell disorder, Bone lesions on imaging, M protein on electrophoresis, Renal dysfunction possible
Waldenström's Macroglobulinemia	IgM monoclonal protein (POEMS is usually IgA or IgG lambda). Lymphoplasmacytic bone marrow infiltration. MYD88 L265P found in >90%. Polyneuropathy is less common and typically anti-MAG mediated. No sclerotic bone lesions or VEGF elevation.	Monoclonal gammopathy, Possible peripheral neuropathy, Organomegaly in advanced disease
Castleman Disease (multicentric)	No clonal plasma cell population. No monoclonal protein. Can co-occur with POEMS (11-30% of POEMS patients have Castleman disease). When isolated, lacks polyneuropathy and sclerotic bone lesions.	Elevated VEGF and IL-6, Lymphadenopathy, Organomegaly, Systemic inflammatory symptoms, Skin changes
Diabetic Neuropathy	History of diabetes mellitus. Primarily axonal (not demyelinating) on nerve conduction studies. No monoclonal protein, no VEGF elevation, no sclerotic bone lesions. Endocrinopathy in POEMS can include glucose intolerance, potentially causing confusion.	Length-dependent sensorimotor polyneuropathy, Progressive distal weakness, Glucose intolerance may be present in both
AL Amyloidosis	Tissue biopsy shows amyloid deposits (Congo red positive). Neuropathy is axonal and painful (small fiber predominant), not demyelinating. Cardiac involvement with restrictive cardiomyopathy. Lambda light chain restriction present but amyloidogenic, not VEGF-producing. No sclerotic bone lesions.	Monoclonal plasma cell disorder (often lambda), Peripheral neuropathy, Organomegaly, Edema, Endocrinopathy
Schnitzler Syndrome	Monoclonal IgM (not lambda-restricted IgA/IgG). Chronic urticarial rash is the hallmark. IL-1-driven autoinflammation (not VEGF-driven). No polyneuropathy, no sclerotic bone lesions. Responds to IL-1 blockade (anakinra/canakinumab).	Monoclonal gammopathy, Bone abnormalities (osteosclerosis in Schnitzler), Organomegaly possible, Skin changes

Hypotheses (4)

Hypothesis	Domain	Status	Evidence score	Studies	Evidence for	Evidence against
VEGF is the central driver of multisystem disease manifestations in POEMS syndrome	pathogenesis	leading	85/100	35	Serum VEGF levels are 5-10x normal and correlate with disease activity VEGF explains vascular permeability (edema, effusions, organomegaly) VEGF response to treatment predicts clinical improvement Serum VEGF >1000 pg/mL has ~100% sensitivity for POEMS in neuropathy patients	Bevacizumab (anti-VEGF) fails to produce consistent clinical benefit despite lowering VEGF VEGF mRNA is NOT upregulated in clonal plasma cells themselves (Isshiki 2022) Multiple other cytokines (IL-6, IL-12, TNF-alpha) are also elevated Some treated patients improve clinically before VEGF normalizes
VEGF-induced vascular permeability is the primary mechanism of organomegaly, edema, and effusions	organ_damage	leading	75/100	20	VEGF is the most potent known vascular permeability factor Extravascular volume overload (edema, ascites, pleural effusions) correlates with VEGF levels Organomegaly resolves with treatments that lower VEGF Papilledema explained by VEGF-driven increased endoneural and intracranial pressure	Not all patients with very high VEGF develop effusions Other cytokines (IL-1beta, TNF-alpha) also increase vascular permeability Bevacizumab reduces VEGF but does not consistently resolve effusions
Clonal plasma cells drive disease via a cytokine cascade initiated by IL-6, not direct VEGF production	pathogenesis	emerging	65/100	12	Single-cell RNA-Seq shows VEGF mRNA is NOT upregulated in POEMS clonal plasma cells IL-6 is overexpressed by POEMS clones and is a potent inducer of VEGF in bystander cells IL-6 elevation also seen in co-occurring Castleman disease POEMS clones have a distinct transcriptional profile (CD19+, CD138+, MHC class II-low)	IL-6-targeted therapy has not been systematically tested in POEMS Based on limited single-cell studies with small sample sizes The intermediate cell types producing VEGF in response to IL-6 are not fully characterized
Sclerotic bone lesions result from cytokine-mediated osteoblast activation rather than direct tumor infiltration	bone_pathology	competing	55/100	8	VEGF stimulates osteoblast activity and new bone formation Bone lesions are sclerotic (not lytic as in myeloma), consistent with osteoblast activation Plasma cell burden is characteristically small, arguing against direct tumor-mediated destruction Other osteoblast-stimulating cytokines (IL-6, TGF-beta) are elevated	Mechanism not directly demonstrated in POEMS bone tissue Some patients have mixed lytic-sclerotic lesions Radiotherapy to isolated plasmacytomas resolves local lesions, suggesting some tumor-mediated component

Open Questions (5)

Why is POEMS syndrome almost exclusively lambda light chain restricted?
Over 95% of POEMS patients have lambda-restricted monoclonal protein, with stereotypic IGLV1-44 or IGLV1-40 gene usage. This extreme restriction suggests antigen-driven clonal selection, but the triggering antigen remains unknown.
Why are bone lesions sclerotic rather than lytic in POEMS, unlike other plasma cell dyscrasias?
Multiple myeloma causes lytic bone destruction, yet POEMS — also driven by clonal plasma cells — produces osteosclerotic lesions. The mechanism of this divergence is poorly understood but may relate to the cytokine milieu (high VEGF, IL-6) preferentially stimulating osteoblasts.
Why is thrombocytosis/polycythemia a feature of POEMS rather than the cytopenias seen in myeloma?
POEMS patients frequently have elevated platelet counts and sometimes polycythemia, the opposite of the cytopenias typical of myeloma. This may relate to thrombopoietin or erythropoietin stimulation by VEGF or other cytokines, but the mechanism is unproven.
By what mechanism does VEGF cause the demyelinating polyneuropathy characteristic of POEMS?
The neuropathy in POEMS is a length-dependent demyelinating sensorimotor polyneuropathy with uniform slowing, distinct from CIDP. VEGF likely increases endoneural vascular permeability, exposing myelin to serum cytokines and complement, but the exact pathogenic cascade is not established.
What is the optimal VEGF level cutoff for monitoring treatment response and predicting relapse?
VEGF is used as a biomarker for diagnosis and monitoring, but there is no consensus on the threshold that defines adequate treatment response. Plasma VEGF avoids platelet-derived confounding seen with serum VEGF, but standardized cutoffs are lacking.

Complications (6)

Complication	Risk	Timeframe	Description	Monitoring
Respiratory failure	~20-30% develop significant pulmonary involvement	Can occur at presentation or with disease progression	Restrictive lung disease from pleural effusions, diaphragmatic weakness, or pulmonary parenchymal involvement. Pleural effusions are common and can be recurrent, requiring repeated thoracentesis.	Pulmonary function tests; chest imaging every 6-12 months; pulse oximetry
Pulmonary hypertension	~25-35% of patients	May present at diagnosis or develop during disease course	Pulmonary arterial hypertension, likely VEGF-mediated, is an important cause of morbidity and mortality. Associated with inferior survival. Can improve or resolve with effective treatment of the underlying plasma cell clone.	Echocardiography every 6-12 months; right heart catheterization if suspected; BNP/NT-proBNP
Stroke and thrombotic events	~10-20%	Throughout disease course; heightened risk in active disease	Arterial and venous thrombotic events including stroke, deep vein thrombosis, and pulmonary embolism. Thrombocytosis and VEGF-driven endothelial activation contribute to a prothrombotic state.	Clinical vigilance for thrombotic symptoms; consider thromboprophylaxis during active disease and with immunomodulatory therapy (lenalidomide, thalidomide)
Renal failure	~10-15%	Progressive, often years into disease	Renal involvement can include membranoproliferative glomerulonephritis, thrombotic microangiopathy, or renal artery stenosis. eGFR is an independent prognostic factor. May be exacerbated by treatment-related toxicity.	Serum creatinine, eGFR, urinalysis with proteinuria assessment every 3-6 months
Disease progression or clonal transformation	~30% experience relapse/progression	Median time to relapse ~42 months after first-line therapy	Despite good initial responses, disease can relapse or progress. Rarely, transformation to frank multiple myeloma or high-grade lymphoma can occur. Complete hematologic response is associated with PFS of 88%, while incomplete response predicts earlier progression.	Serial SPEP/immunofixation, VEGF levels, and clinical assessment every 3-6 months; PET-CT if progression suspected
Treatment-related mortality (autologous transplant)	~2-5% transplant-related mortality	Within 100 days of transplant	Autologous stem cell transplant carries engraftment syndrome risk (higher than in myeloma ASCT), potential for multi-organ complications including capillary leak syndrome, and infection-related mortality. Patients with significant pulmonary hypertension, pleural effusions, or renal dysfunction are at higher risk.	Pre-transplant pulmonary function tests, echocardiography, and renal function assessment; close post-transplant monitoring for engraftment syndrome

Sources (33)

Ref	Authors	Title	Journal	Year	Category	Type	Grade	Link
A6	Dispenzieri A	POEMS syndrome: Update on diagnosis, risk-stratification, and management	Am J Hematol	2023	reviews	narrative review	A	DOI
D4	Isshiki T, Yaguchi T, Okuyama Y, et al.	Unraveling unique features of plasma cell clones in POEMS syndrome with single-cell analysis	JCI Insight	2022	genetics	cohort	B	DOI
A5	Dispenzieri A	POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management	Am J Hematol	2021	reviews	narrative review	A	DOI
D3	Chen J, Gao XM, Zhao H, et al.	A highly heterogeneous mutational pattern in POEMS syndrome	Leukemia	2021	genetics	cohort	B	DOI
J1	He H, Zhao D, Jiang H, et al.	Bortezomib plus dexamethasone as first-line therapy for patients with POEMS syndrome	Ann Hematol	2021	treatment	cohort	B	DOI
D5	Abe D, Sakaue T, Kamata T, et al.	Immunoglobulin variable domain high-throughput sequencing reveals specific novel mutational patterns in POEMS syndrome	Blood	2020	genetics	cohort	B	DOI
A4	Dispenzieri A	POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management	Am J Hematol	2019	reviews	narrative review	A	DOI
A7	Suichi T, Misawa S, Sato Y, et al.	Prevalence, clinical profiles, and prognosis of POEMS syndrome in Japanese nationwide survey	Neurology	2019	epidemiology	cohort	B	DOI
D2	Nagao Y, Mimura N, Takeda J, et al.	Genetic and transcriptional landscape of plasma cells in POEMS syndrome	Leukemia	2019	genetics	cohort	B	DOI
E3	Caimari F, Keddie S, Lunn MP, et al.	Prevalence and Course of Endocrinopathy in POEMS Syndrome	J Clin Endocrinol Metab	2019	clinical	cohort	B	DOI
M1	Zhao H, Cai H, Wang C, et al.	What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone?	Am J Hematol	2019	treatment	cohort	B	DOI
A8	Keddie S, Lunn MP	POEMS syndrome	Curr Opin Neurol	2018	reviews	narrative review	B	PubMed
B4	Pihan M, Keddie S, D'Sa S, et al.	Raised VEGF: High sensitivity and specificity in the diagnosis of POEMS syndrome	Neurol Neuroimmunol Neuroinflamm	2018	diagnostics	cohort	B	DOI
H1	He H, Zhao D, Jiang H, et al.	A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed POEMS syndrome	Am J Hematol	2018	treatment	cohort	B	DOI
K1	Misawa S, Sato Y, Katayama K, et al.	Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial	Lancet Neurol	2016	treatment	RCT	A	DOI
M2	Kourelis TV, Buadi FK, Kumar SK, et al.	Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment	Am J Hematol	2016	epidemiology	cohort	B	DOI
H2	Li J, Zhang W, Jiao L, et al.	Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome	Eur J Haematol	2015	treatment	cohort	C	DOI
E1	Shi X, Luo Y, Zhang L, et al.	Cutaneous manifestations in patients with POEMS syndrome	Am J Med	2013	clinical	cohort	B	PubMed
F1	Humeniuk MS, Gertz MA, Lacy MQ, et al.	Outcomes of patients with POEMS syndrome treated initially with radiation	Blood	2013	treatment	cohort	B	DOI
L1	Kanai K, Kuwabara S, Misawa S, Hattori T	Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome	J Neurol	2013	treatment	case series	C	PubMed
B2	Kanai K, Kuwabara S, Misawa S, Hattori T	Markedly upregulated serum interleukin-12 as a novel biomarker in POEMS syndrome	Neurology	2012	pathophysiology	cohort	B	DOI
C1	Mauermann ML, Sorenson EJ, Dispenzieri A, et al.	Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP	J Neurol Neurosurg Psychiatry	2012	diagnostics	cohort	B	DOI
C2	Nasu S, Misawa S, Sekiguchi Y, et al.	Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy	J Neurol Sci	2012	diagnostics	cohort	B	PubMed
G1	D'Souza A, Lacy M, Gertz M, et al.	Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience	Blood	2012	treatment	cohort	B	DOI
B3	D'Souza A, Hayman SR, Buadi F, et al.	The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome	Blood	2011	diagnostics	cohort	B	DOI
I1	Li J, Zhou DB, Huang Z, et al.	Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome	Blood	2011	treatment	cohort	B	DOI
D1	Abe D, Nakaseko C, Takeuchi M, et al.	Restrictive usage of monoclonal immunoglobulin lambda light chain germline in POEMS syndrome	Blood	2008	genetics	case series	B	DOI
A3	Dispenzieri A	POEMS syndrome	Blood Rev	2007	reviews	narrative review	B	DOI
E2	Gandhi GY, Basu R, Dispenzieri A, Basu A, Montori VM, Brennan MD	Endocrinopathy in POEMS syndrome: the Mayo Clinic experience	Mayo Clin Proc	2007	clinical	cohort	B	DOI
A2	Dispenzieri A, Kyle RA, Lacy MQ, et al.	POEMS syndrome: definitions and long-term outcome	Blood	2003	epidemiology	cohort	B	DOI
C3	Sung JY, Kuwabara S, Ogawara K, Kanai K, Hattori T	Patterns of nerve conduction abnormalities in POEMS syndrome	Muscle Nerve	2002	diagnostics	cohort	C	PubMed
B1	Gherardi RK, Belec L, Soubrier M, et al.	Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome	Blood	1996	pathophysiology	cohort	B	PubMed
A1	Bardwick PA, Zvaifler NJ, Gill GN, Newman D, Greenway GD, Resnick DL	Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome	Medicine (Baltimore)	1980	reviews	case series	B	PubMed

Pathophysiology Narrative

POEMS syndrome is a paraneoplastic disorder in which a small clonal plasma cell population drives multi-organ damage primarily through massive VEGF overproduction. Serum VEGF levels are typically 5-10 fold above normal and correlate directly with disease activity.

The mechanism of VEGF elevation is complex and incompletely understood. Single-cell RNA sequencing (Isshiki et al. 2022) showed that VEGF mRNA is paradoxically NOT upregulated in the clonal plasma cells themselves. Instead, IL-6 — which is overexpressed by the clones — acts as a potent inducer of VEGF production by surrounding cells. This places IL-6 upstream of VEGF in the pathogenic cascade.

The cytokine milieu in POEMS is broadly inflammatory: IL-1beta, IL-6, TNF-alpha, and IL-12 are all elevated, with IL-12 and VEGF being the most consistently and markedly raised. VEGF drives increased vascular permeability, leading to extravascular volume overload (edema, ascites, pleural effusions), papilledema, and organomegaly. In peripheral nerves, increased endoneural pressure and exposure of myelin to serum cytokines and complement causes the characteristic demyelinating polyneuropathy.

The near-universal lambda light chain restriction (>95%) with stereotypic IGLV1-44 or IGLV1-40 gene usage suggests a highly specific antigen-driven B-cell selection process, though the triggering antigen remains unknown.

The sclerotic (rather than lytic) bone lesions distinguish POEMS from multiple myeloma. The osteosclerosis likely reflects VEGF-driven osteoblast stimulation. Castleman disease (present in 11-30% of cases) shares VEGF and IL-6 elevation, explaining their frequent co-occurrence.

The failure of bevacizumab (anti-VEGF monoclonal antibody) to produce consistent clinical benefit — despite lowering VEGF levels — demonstrates that multiple cytokines and pathways contribute to organ damage beyond VEGF alone.

Genetic Basis Narrative

POEMS syndrome has a highly heterogeneous somatic mutational landscape that is distinct from multiple myeloma. Whole-exome sequencing studies have identified hundreds of somatic mutations but no single unifying driver.

Nagao et al. (2019) performed WES on plasma cells from 20 patients, finding 308 somatic mutations across 285 genes. Seven recurrently mutated genes were identified: KLHL6, LTB, EHD1, EML4, HEPHL1, HIPK1, and PCDH10. Critically, none of the driver genes characteristic of myeloma (NRAS, KRAS, BRAF, TP53) were detected.

Chen et al. (2021) confirmed the heterogeneity in 42 patients, identifying significantly mutated genes including LILRB1, HEATR9, and FMNL2, along with known driver genes MYD88, NFKB2, STAT3, and CUX1. The two studies were concordant in confirming heterogeneous profiles but largely discordant in specific mutated genes.

The most distinctive molecular feature is the near-universal restriction to lambda light chain with stereotypic IGLV gene usage. Abe et al. (2008) showed IGLV1-44*01 (in ~80% of cases) and IGLV1-40*01 (in ~20%) with specific conserved amino acid changes in CDR1 and FR2 regions (confirmed by Abe et al. 2020 via high-throughput sequencing). This extreme restriction suggests an antigen-driven clonal selection process unique to POEMS.

Single-cell analysis (Isshiki et al. 2022) revealed that POEMS clones are CD19+, CD138+, MHC class II-low, with significantly lower c-MYC and CCND1 expression than myeloma clones — explaining their characteristically small clone size.